Jardiance® (empagliflozin) approved in Europe for the treatment of heart failure with reduced ejection fraction

INGELHEIM, Germany–(BUSINESS WIRE)–The European Commission has granted marketing authorization for Jardiance® (empagliflozin) as a treatment for adults with symptomatic chronic heart fai…